Updates are available Correction dated 2020-08-03
Click to view Correction: https://doi.org/10.1186/s40478-020-01005-5
-
Authors
Thal, Dietmar Rudolf http://orcid.org/0000-0002-1036-1075
Ronisz, Alicja
Tousseyn, Thomas
Rijal Upadhaya, Ajeet
Balakrishnan, Karthikeyan
Vandenberghe, Rik
Vandenbulcke, Mathieu
von Arnim, Christine A. F.
Otto, Markus
Beach, Thomas G.
Lilja, Johan
Heurling, Kerstin
Chakrabarty, Aruna
Ismail, Azzam
Buckley, Christopher
Smith, Adrian P. L.
Kumar, Sathish
Farrar, Gill
Walter, Jochen
-
Funding
Funding for this research was provided by:
GE Healthcare (GE-067-007; GE-067-026)
Deutsche Forschungsgemeinschaft (TH624 4-1, 4-2, 6-1, WA-1477 6-2)
Alzheimer Forschung Initiative (10810; 13803, 12854, 17011)
Fonds Wetenschappelijk Onderzoek (G0F8516N)
Agentschap voor Innovatie door Wetenschap en Technologie (135043)
- License Information
-
More Information
Article History
Received: 24 October 2019
Accepted: 28 October 2019
First Online: 14 November 2019
Change Date: 3 August 2020
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via the original article.
Ethics approval and consent to participate
: All autopsies were carried out according to local legislation with appropriate consent. Ethical approval for the use of cases from cohort 1 was granted by the ethical committee of Ulm University (Germany), and for the cohort 2 cases by the UZ/KU-Leuven ethical committee (Belgium). Cohort 3 was obtained for the efficacy analysis of the [<sup>18</sup>F] flutemetamol phase III autopsy study ( identifiers NCT01165554, and NCT02090855) [, ]. Local institutional review boards or ethics committees approved the study protocols before initiation [, ]. This study covering the retrospective analysis of samples and data from the three cohorts was approved by the UZ/KU-Leuven ethical committee (S-59295) (Belgium).
: Not applicable for this study, which did not use person’s data. Only anonymized or pseudonymized data were processed.
: DRT received consultancies from GE-Healthcare (UK) and Covance Laboratories (UK), speaker honorarium from Novartis Pharma Basel (Switzerland), travel reimbursement from GE-Healthcare (UK), and UCB (Belgium), and collaborated with GE-Healthcare (UK), Novartis Pharma Basel (Switzerland), Probiodrug (Germany), and Janssen Pharmaceutical Companies (Belgium). TGB received a consultancy from GE-Healthcare (UK). GF, CB, APLS are employees of GE-Healthcare (UK, USA). JL and KH were employees of GE-Healthcare (Sweden). JL is currently employee of Hermes Medical Solutions (Sweden). AC and AI received personal fees from GE-Healthcare via the University of Leeds. CAFvA received honoraria from serving on the scientific advisory board of Nutricia GmbH (2014), Roche (2018) and Hongkong University Research council (2014) and has received funding for travel and speaker honoraria from Nutricia GmbH (2014–2015), Lilly Deutschland GmbH (2013–2016), Desitin Arzneimittel GmbH (2014), Biogen (2016–2018), Roche (2017–2018) and Dr. Willmar Schwabe GmbH &Co. KG (2014–2015). MO received honoraria from serving on the advisory board of Axon and Fujirebio.
